Polymeric nanoparticle mediated inhibition of miR-21 with enhanced miR-124 expression for combinatorial glioblastoma therapy

Liu, Yuanyuan; Zheng, Meng; Jiao, Mingzhu; Yan, Chengnan; Xu, Sen; Du, Qiuli; Morsch, Marco; Yin, Jinlong; Shi, Bingyang

doi:10.1016/j.biomaterials.2021.121036

Cited by 37 publications

(21 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results revealed promising outcomes in reducing the tumorigenesis of the glioblastoma in the xenograft mice model. Different miRNAs expressed in the four subtypes of medulloblastoma [82,83,[93][94][95][96][97][98][99][100].…”

Section: Nanoparticles and Mirnasmentioning

confidence: 99%

MicroRNA Biomarkers in Primary Brain Malignancies

Mustafov¹,

Seriah²,

Malik³

et al. 2023

Epigenetics - Regulation and New Perspectives

View full text Add to dashboard Cite

Despite the concerted efforts within the management of brain malignancies over the past few decades, primary brain cancers remain an obscure challenge with unfavourable outcomes for the patients. Glioblastomas (GBM) and medulloblastomas afford the most prevalent brain tumours and account for markedly high mortality rates within affected patients. The unmet clinical requirements for an early diagnostic biomarker and effective treatment have shed light onto microRNAs (miRNAs). These are small, endogenous noncoding RNAs involved in a wide spectrum of biological processes, such as post-translational modification, tumorigenesis, angiogenesis, invasiveness, and apoptosis. Increased expression of miR-21 has been shown to have devastating effects upon patients with brain tumours, and it could be used as a diagnostic biomarker and an early relapse indicator. miRNAs such as miR-128a, miR-34a, miR-7 and miR-1253 have demonstrated tumour suppressive properties and could serve as putative therapeutic agents. MiRNA signatures, such as miR-21 and miR-10b could be incorporated as potential prognostic indicators for advanced and metastatic brain malignancies, whereas miR-221/222 cluster has a therapeutic potential to sensitise cancerous cells towards radiotherapy. Herein, we summarised current knowledge on how miRNAs with significant role in glioblastomas and medulloblastomas specifically can be effectively used as promising brain cancer diagnostics, prognostics, and therapeutics.

show abstract

Section: Nanoparticles and Mirnasmentioning

confidence: 99%

MicroRNA Biomarkers in Primary Brain Malignancies

Mustafov¹,

Seriah²,

Malik³

et al. 2023

Epigenetics - Regulation and New Perspectives

View full text Add to dashboard Cite

show abstract

“…Angiopep-2 has also been involved in miRNA-directed nanotherapy. Liu and coworkers [121] used polymeric NPs to simultaneously supplement the function of miR-124 and inhibit the function of miR-21 to treat glioblastoma. Co-delivery of a miR-124 mimic and anti-miR-21 regulated the mutant RAS/PI3K/PTEN/AKT signaling pathway in tumor cells.…”

Section: Nucleic Acid Deliverymentioning

confidence: 99%

Angiopep-2-Modified Nanoparticles for Brain-Directed Delivery of Therapeutics: A Review

Habib

Singh

2022

Polymers

View full text Add to dashboard Cite

Nanotechnology has opened up a world of possibilities for the treatment of brain disorders. Nanosystems can be designed to encapsulate, carry, and deliver a variety of therapeutic agents, including drugs and nucleic acids. Nanoparticles may also be formulated to contain photosensitizers or, on their own, serve as photothermal conversion agents for phototherapy. Furthermore, nano-delivery agents can enhance the efficacy of contrast agents for improved brain imaging and diagnostics. However, effective nano-delivery to the brain is seriously hampered by the formidable blood–brain barrier (BBB). Advances in understanding natural transport routes across the BBB have led to receptor-mediated transcytosis being exploited as a possible means of nanoparticle uptake. In this regard, the oligopeptide Angiopep-2, which has high BBB transcytosis capacity, has been utilized as a targeting ligand. Various organic and inorganic nanostructures have been functionalized with Angiopep-2 to direct therapeutic and diagnostic agents to the brain. Not only have these shown great promise in the treatment and diagnosis of brain cancer but they have also been investigated for the treatment of brain injury, stroke, epilepsy, Parkinson’s disease, and Alzheimer’s disease. This review focuses on studies conducted from 2010 to 2021 with Angiopep-2-modified nanoparticles aimed at the treatment and diagnosis of brain disorders.

show abstract

“…Flower-shaped SiO₂-PEI nanoparticles with miR-let-7c-5p are able to suppress cervical cancer [ 115 ]. Moreover, Liu et al (2021) created stabilized polymeric nanoparticles for the co-delivery and release of miR-124 and anti-miR-21, regulating the tumourigenesis- and angiogenesis-signalling pathways of treated glioblastoma cells, and consequently, resulting in the inhibition of tumour progression [ 116 ].…”

Section: Cancer Treatmentmentioning

confidence: 99%

Role of Nano-miRNAs in Diagnostics and Therapeutics

Coradduzza

Bellu

Congiargiu

et al. 2022

IJMS

View full text Add to dashboard Cite

MicroRNAs (miRNA) are key regulators of gene expression, controlling different biological processes such as cellular development, differentiation, proliferation, metabolism, and apoptosis. The relationships between miRNA expression and the onset and progression of different diseases, such as tumours, cardiovascular and rheumatic diseases, and neurological disorders, are well known. A nanotechnology-based approach could match miRNA delivery and detection to move beyond the proof-of-concept stage. Different kinds of nanotechnologies can have a major impact on the diagnosis and treatment of miRNA-related diseases such as cancer. Developing novel methodologies aimed at clinical practice represents a big challenge for the early diagnosis of specific diseases. Within this context, nanotechnology represents a wide emerging area at the forefront of research over the last two decades, whose potential has yet to be fully attained. Nanomedicine, derived from nanotechnology, can exploit the unique properties of nanometer-sized particles for diagnostic and therapeutic purposes. Through nanomedicine, specific treatment to counteract only cancer-cell proliferation will be improved, while leaving healthy cells intact. In this review, we dissect the properties of different nanocarriers and their roles in the early detection and treatment of cancer.

show abstract

Polymeric nanoparticle mediated inhibition of miR-21 with enhanced miR-124 expression for combinatorial glioblastoma therapy

Cited by 37 publications

References 47 publications

MicroRNA Biomarkers in Primary Brain Malignancies

MicroRNA Biomarkers in Primary Brain Malignancies

Angiopep-2-Modified Nanoparticles for Brain-Directed Delivery of Therapeutics: A Review

Role of Nano-miRNAs in Diagnostics and Therapeutics

Contact Info

Product

Resources

About